Conduct interim analysis of the HOPE-3 clinical trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Nov 2022
- Due
- 30 Jun 2023
- Delivered
- January 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planned interim analysis of HOPE-3 expected by mid-2023”
What we found
Evidence strength A What the grades mean
The company missed the mid-2023 deadline, pushing the interim analysis to the fourth quarter of 2023, with the milestone payment for the completed analysis received in January 2024.
-
A Capricor Therapeutics, Inc. 10-Q filed 2023-08-08
“We plan to complete enrollment and report the outcome from the interim analysis in the fourth quarter of 2023.” ✓ confirmed on the page
-
A Capricor Therapeutics, Inc. 10-K filed 2024-03-11
“The first milestone payment of $10.0 million was paid upon completion of the interim futility analysis of the HOPE-3 trial... Capricor received this milestone payment from Nippon Shinyaku in January 2024.” ✓ confirmed on the page
Market reaction: the shares moved +27.6% against the S&P 500 over the three sessions around the disclosure (7 Aug 2023 to 10 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +184 days
- 3 versions
-
Version 1 · original · stated 10 Nov 2022
Deadline 30 Jun 2023 (“mid-2023”) · wording aspirational
-
Version 2 · stated 15 Mar 2023
Deadline 31 Dec 2023 (“fourth quarter of 2023”) · wording expected
“plan to report the results of our interim analysis in the fourth quarter of 2023”
-
Version 3 · stated 11 May 2023
Deadline 31 Dec 2023 (“fourth quarter of 2023”) · wording firm
“we remain on track to report the interim analysis in the fourth quarter of 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Conduct
- Deliverable
- HOPE-3 interim analysis
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-CAPR-002519 · Corrections policy